Overview

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Status:
Completed

Trial end date:
2021-07-01

Target enrollment:

Participant gender:

Summary

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Phase:

Phase 1

Details

Lead Sponsor:

Corvus Pharmaceuticals, Inc.

Collaborator:

Genentech, Inc.

Treatments:

Antibodies, Monoclonal
Atezolizumab